Cargando…
Early Discontinuation of Aspirin Among Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention with a Drug-Eluting Stent: A Meta-Analysis
KEY POINTS: P2Y12 inhibitor monotherapy after 1–3 months of dual antiplatelet therapy (DAPT) decreases the risk of clinically significant bleeding when compared with 12 months of DAPT in patients with CKD treated with a drug-eluting stent. There is no significant difference in the risk of cardiovasc...
Autores principales: | Festa, Maria Carolina, Rasasingam, Sathiepan, Sharma, Abhinav, Mavrakanas, Thomas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Nephrology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547225/ https://www.ncbi.nlm.nih.gov/pubmed/37768893 http://dx.doi.org/10.34067/KID.0000000000000223 |
Ejemplares similares
-
Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023) -
Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021) -
One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016) -
Newer-Generation Drug-Eluting Stents in Patients Undergoing Complex Percutaneous Coronary Intervention
por: Otsuka, Kenichiro
Publicado: (2021) -
Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention
por: Baschet, Louise, et al.
Publicado: (2016)